Mechanism of Action: UGT1A9 Inhibitors

Drugs with Mechanism of Action: UGT1A9 Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Inc	ALVAIZ	eltrombopag choline	TABLET;ORAL	216774-001	Nov 29, 2023		RX	Yes	No	11,072,586		Y	Y
Teva Pharms Inc	ALVAIZ	eltrombopag choline	TABLET;ORAL	216774-002	Nov 29, 2023		RX	Yes	No	11,072,586		Y	Y
Teva Pharms Inc	ALVAIZ	eltrombopag choline	TABLET;ORAL	216774-003	Nov 29, 2023		RX	Yes	No	11,072,586		Y	Y
Teva Pharms Inc	ALVAIZ	eltrombopag choline	TABLET;ORAL	216774-004	Nov 29, 2023		RX	Yes	Yes	11,072,586		Y	Y
Amneal	ELTROMBOPAG OLAMINE	eltrombopag olamine	TABLET;ORAL	212884-001	Jan 14, 2026	AB	RX	No	No
Zydus Pharms	ELTROMBOPAG OLAMINE	eltrombopag olamine	TABLET;ORAL	216281-002	Jan 14, 2026	AB	RX	No	No
Hikma	ELTROMBOPAG OLAMINE	eltrombopag olamine	TABLET;ORAL	220033-001	Apr 8, 2026	AB	RX	No	No

Last updated: June 27, 2026

UGT1A9 Inhibitors Market Dynamics and Patent Landscape: Who Holds the IP, What Is Expiring, and Where Generic or Biosimilar Risk Exists

UGT1A9 inhibitors sit at the intersection of drug-drug interaction (DDI) management and exposure optimization for drugs primarily cleared by UGT1A9-mediated glucuronidation. The patent landscape is dominated by (1) small-molecule “basic scaffold” composition-of-matter (COM) and (2) downstream method-of-use (MoU) claims for DDI reduction, coadministration regimens, and exposure tailoring. Commercially, adoption depends less on standalone blockbuster potential and more on each inhibitor’s ability to (a) reliably inhibit UGT1A9 at clinically relevant exposures, (b) avoid clinically meaningful off-target effects, and (c) win partner validation through regulatory-grade DDI data packages and prescribing outcomes.

The market dynamics for UGT1A9 inhibitors remain “platform-like”: most value is captured when an inhibitor becomes part of a combination strategy (coadministration with a UGT1A9 substrate), or when it is embedded into development programs for UGT1A9-mediated exposure control.

What patents protect most UGT1A9 inhibitor IP estates? Typically COM claims for inhibitor scaffolds, plus formulation and dosing regimen claims. Practical enforcement hinges on the inhibitor compound, not the DDI indication alone, because DDI method claims often face narrower validity and harder infringement proof.

Generic entry risk for UGT1A9 inhibitors is typically low in early phases because the UGT1A9 inhibitor class has fewer validated, widely marketed products than major CYP inhibitor markets; when generic risk appears, it is tied to Orange Book listings for finished drug products. For substances without an FDA-approved reference product listing, “generic” risk shifts to patent challenges and licensing rather than ANDA-style entry.

Actionable bottom line: watch the expiration of core inhibitor COM families and any “second-wave” patent filings (e.g., specific dosing regimens, specific UGT1A9 substrates, or new formulations) that can extend exclusivity around coadministration strategies.

---

Which drugs use UGT1A9 inhibition to drive exposure, and what market dynamics shape uptake?

UGT1A9 inhibitors are used to modify systemic exposure of UGT1A9 substrate drugs, typically to address:

• Steady-state exposure reduction (for toxicity mitigation when a substrate has a narrow therapeutic window).
• Exposure normalization across patient subgroups (polymorphism, hepatic impairment, or concomitant coadministration effects).
• DDI management to ensure predictable pharmacokinetics in combination therapy.

Market adoption is driven by regulatory and clinical utility rather than therapeutic area. Buyers (sponsors, formulators, and guideline stewards) value inhibitors that reduce uncertainty in DDI labeling and translate into simpler coadministration without dose reductions.

What are the practical “buy signals” for a UGT1A9 inhibitor program?

• Clear clinical DDI phenotype for UGT1A9 substrates in human studies.
• Minimal induction/inhibition of other major enzymes and transporters that would trigger safety or labeling conflicts.
• Reproducible inhibition across dose range and formulation conditions.
• Regulator-ready exposure rationale: inhibitor concentration-response that supports label language and dosing.

What drives pricing and reimbursement dynamics?

Pricing usually follows the value of exposure control in combination:

• If the UGT1A9 inhibitor enables maintaining the substrate at effective doses without added monitoring, payers accept a higher premium.
• If value is confined to rare DDI scenarios or requires complex monitoring, adoption is limited and exclusivity value compresses.

---

What patents protect UGT1A9 inhibitors: composition-of-matter vs method-of-use vs formulation IP?

UGT1A9 inhibitor patent estates commonly cluster into three layers.

1) Composition-of-matter (COM)

COM families are typically the most enforceable asset because they cover the inhibitor chemical entity itself, regardless of the substrate or clinical context.

Typical claim structure

• Generic and specific inhibitor scaffolds
• Defined substituents on key positions controlling potency and selectivity
• Salts, solvates, polymorphs, and prodrugs (when relevant)

2) Method-of-use (MoU)

MoU claims often cover:

• Co-administration with a UGT1A9 substrate
• Reducing/controlling exposure of UGT1A9 substrates
• Dosing regimens based on inhibitor and substrate schedules

MoU claims can be valuable if infringement is clear (prescribing and administering the claimed regimen), but they can also be harder to enforce if clinicians do not follow exact schedules or if the substrate is not within the claim definitions.

3) Formulation and dosing regimen patents

Formulation IP can extend effective exclusivity:

• Tablet/capsule compositions
• Controlled release or exposure-stabilizing delivery
• Specific dose regimens tied to achieving a target inhibition window

---

How strong is the patent estate for UGT1A9 inhibitors: what claim types tend to survive challenges?

Strength is driven by claim breadth, written description support, and enforceability across jurisdictions.

Patent estate attributes that increase strength

• Broad scaffold coverage with strong examples
• Clear teaching enabling one skilled in the art to make and use the inhibitor
• Consolidation of COM coverage with early filing priority to prevent “thicket” gaps

Patent estate attributes that weaken strength

• Overly narrow MoU claims requiring exact patient or dosing conditions
• Attempts to broaden beyond the original disclosure
• Claims that depend on specific clinical exposure targets without robust support

---

When does UGT1A9 inhibitor exclusivity expire, and what drives “evergreening” risk?

For UGT1A9 inhibitors, “evergreening” typically occurs through:

• Secondary COM filings (new salts, polymorphs, or analog series)
• New dosing regimens aligned to clinical practice
• Formulation patents that protect a specific release profile

Exclusivity expiration is not only about patent term

• For FDA products, data and marketing exclusivity can extend beyond primary patent expiration.
• For combination strategies, the inhibitor may remain protected even after COM expiration if formulation or MoU patents survive.

Practical watchlist

• Second priority filings after initial scaffold COM
• Continuations/divisionals that extend claim coverage
• Patent “clustering” that creates a practical blocking position for generic entry even when headline expiration dates look near

---

What is the Orange Book status of UGT1A9 inhibitors, and what does it mean for generic entry scenarios?

Whether generic risk materializes through ANDAs depends on:

• Existence of an FDA-approved reference product with a listing
• Whether relevant patents are listed for the active ingredient and dosage form
• Whether relevant patents are challengeable under Paragraph IV

Key linkage for ANDA pathways

• If a UGT1A9 inhibitor is not listed in the Orange Book, generic approval may still occur through other regulatory mechanisms, but typical Paragraph IV timing leverage is absent.

Commercial implication

• If no Orange Book listing exists, the sponsor’s enforcement posture shifts to patent litigation and licensing, not automatic statutory timelines.

(Note: Specific Orange Book listing counts and individual patent numbers cannot be provided here without an authoritative product-level dataset for the current set of UGT1A9 inhibitors and their FDA listings.)

---

Which companies hold UGT1A9 inhibitor patents, and where are the filing concentrations by jurisdiction?

UGT1A9 inhibitor IP is usually concentrated among:

• Global pharma and large specialty companies with DDI program capabilities
• Academic transfer entities for early scaffold inventions
• Contract research-to-patent pipeline groups that generate follow-on compounds and specific MoU filings

Jurisdictional strategy typically follows:

• US and EP for enforceability and litigation leverage
• JP and CN where pharma patent filing strategies prioritize broad coverage and local enforcement pathways
• KR and additional jurisdictions depending on commercial intent and partnership structure

(Note: Company-by-company patent holder assignments require a jurisdiction- and compound-specific patent corpus to produce accurate named entities and filing counts.)

---

Which UGT1A9 inhibitor patents are likely targets for Paragraph IV challenges, and why?

Paragraph IV challenges target listed patents where:

• A generic product can be substituted without therapeutic mismatch
• The challenger can certify non-infringement or invalidity credibly
• The challenged patents are not protected by strong claim construction or early priority defects

For UGT1A9 inhibitors, Paragraph IV threats often focus on:

• COM patents with the narrowest claim interpretation support
• Later-filed analog series that may face written description constraints
• Formulation patents if the generic can switch dosage form while preserving clinical equivalence

Key risk vector

• Even if COM is hard to attack, MoU and dosing regimen patents can be avoided by launching a product without adopting the claimed administration pattern, depending on claim drafting and enforcement environment.

---

What UGT1A9 inhibitor patent litigation affects developers and generics?

UGT1A9 inhibitor litigation, when it occurs, typically reflects:

• Disputes over scope of COM claims (infringement under Markman claim construction)
• Validity arguments around obviousness combining scaffold analogs and prior DDI inhibitor art
• Treatment of continuation/divisional claims and priority dates

Litigation outcomes that matter commercially

• Injunctions affecting launch timing
• Settlement agreements that trade license payments for branded “no launch” commitments
• Carve-outs where generic entry proceeds with design-around (different salt/polymorph or release profile)

(Note: Listing specific cases, dockets, and settlement details requires a litigation docket-level dataset for UGT1A9 inhibitor products.)

---

How do UGT1A9 inhibitors compare with UGT1A1 inhibitors and CYP inhibitors in patent strategy and market value?

Comparative dynamics:

• CYP inhibitors have mature DDI frameworks and broader commercial use cases, leading to denser patent landscapes and more established regulatory pathways.
• UGT1A1 inhibitors have clearer oncology and hemato-critical use patterns and more defined substrate dependency in labeling.
• UGT1A9 inhibitors are more “niche-to-platform,” often enabling combination strategies rather than standalone therapeutic endpoints.

Patent strategy implications

• UGT1A9 inhibitor estates lean toward substrate-specific MoU and regimen patents.
• CYP inhibitor estates historically show large COM blocks plus extensive mechanistic and clinical DDI claim families.
• UGT inhibitor estates face stronger selectivity and off-target requirements, which can narrow real-world use and change infringement analysis.

---

What formulation patents for UGT1A9 inhibitors are most likely to block design-arounds?

Formulation patents often protect:

• Specific excipient systems controlling absorption
• Particle size or solid-state properties
• Controlled-release mechanisms that stabilize inhibitor exposure

Design-around pathways

• Switch to different release profile
• Switch salt form or polymorph if not protected
• Use a different dosage form with bioequivalent pharmacokinetics

Where design-around is hardest

• When the formulation patent ties directly to a defined solid-state form essential for stability and exposure
• When dosing and release profile are tied to achieving a target inhibition window in MoU claims

---

What biosimilar risk exists for UGT1A9 inhibitors, and why is it usually low?

UGT1A9 inhibitors are typically small molecules, not biologics. Biosimilar risk generally does not apply unless a biologic UGT1A9-targeting modality exists (e.g., enzyme-modulating antibodies or gene therapy) which is atypical for this mechanism class.

Accordingly, the competitive threat profile is mainly:

• Small-molecule generic competitors
• Alternate salts/polymorphs
• Formulation and regimen design-arounds

---

What generic launch scenarios exist for UGT1A9 inhibitors: ANDA, authorized generics, and licensing?

Launch pathways usually break into three scenario types:

1. ANDA-style entry (where Orange Book listings exist)

   • Challenger files ANDA and makes Paragraph IV certification
   • Potential 180-day exclusivity to first filer if ANDA is approved promptly
   • Branded firm seeks injunction or pushes settlement

2. Authorized generic or license-based entry

   • Brand grants an entry right to an authorized generics partner
   • Payments and field-of-use restrictions define launch timing and market access

3. Design-around with non-listed claims or different dosage form

   • Generic launches with altered solid-state form or release profile
   • Avoids infringement on formulation or method-of-use patents

Commercial risk is highest when the inhibitor’s primary COM claims are close to expiration and the estate lacks strong formulation coverage.

---

Key takeaways: how to model revenue exposure and patent-driven timing for UGT1A9 inhibitor programs

• UGT1A9 inhibitor value is driven by DDI utility and coadministration success, not monotherapy endpoints.
• IP strength usually concentrates in inhibitor COM plus MoU regimen claims; formulation patents can extend practical exclusivity.
• Generic risk hinges on Orange Book listing existence, listed patent scope, and whether challengers can design around formulation or administration schedule requirements.
• Evergreening risk is usually tied to later priority filings for analogs, salts/polymorphs, and controlled-release formats.
• Litigation and settlements, when present, usually determine launch timing more than headline patent expiration dates.

---

FAQs

1) What does “UGT1A9 inhibitor” mean in regulatory DDI labeling language?

UGT1A9 inhibitors are typically described in the context of altered exposure of UGT1A9 substrates, with recommended dosing adjustments or monitoring in coadministration scenarios depending on clinical DDI findings.

2) Do UGT1A9 inhibitor patents usually list specific UGT1A9 substrates in method-of-use claims?

Method-of-use patents often include substrate classes or enumerated substrate compounds to support infringement and reduce prior art overlap, making substrate selection a key factor in enforcement.

3) Are UGT1A9 inhibitors more protected by COM or by MoU patents?

Most enforcement-heavy assets are COM families, with MoU claims acting as additional coverage where infringement can be established through prescribing and administration patterns.

4) How should sponsors assess generic entry timing for a UGT1A9 inhibitor?

Model the earliest expiration among core COM families, add any formulation or polymorph patent term extensions, and evaluate Orange Book listing impact for ANDA Paragraph IV leverage where applicable.

5) Are controlled-release formulations common in UGT1A9 inhibitor patent estates?

Controlled-release and exposure-stabilizing dosage form patents are common when inhibition needs a stable concentration-time profile, especially when dosing regimens are tied to inhibition windows.

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA. Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Patent and Trademark Office. Patent Center. https://patentscope.wipo.int/ (WIPO gateway)